• 1
    Tougas G, Chen Y, Hwang P, Liu MM, Eggleston A. Prevalence and impact of upper gastrointestinal symptoms in the Canadian population: findings from the DIGEST study. Am J Gastroenterol 1999; 94: 284554.
    Direct Link:
  • 2
    Jones RH, Lydeard SE, Hobbs FD, et al. Dyspepsia in England and Scotland. Gut 1990; 31: 4015.
  • 3
    Colin-Jones R, Bloom B, Bodemar G, et al. Management of dyspepsia: report of a working party. Lancet 1988; 1: 5769.
  • 4
    Veldhuyzen van Zanten SJ, Flook N, Chiba N, et al. An evidence-based approach to the management of patients with uninvestigated dyspepsia in the era of Helicobacter pylori. Can Med Assoc J 2000; 162(12 Suppl.): S3S20.
  • 5
    Chiba N. Definitions of dyspepsia: time for a reappraisal. Eur J Surg 1998; 583(Suppl.): 1423.
  • 6
    Drossman DA, Thompson WG, Talley NJ, Funch-Jensen P, Jansens J, Whitehead WE. Identification of subgroups of functional intestinal disorders. Gastroenterol Int 1990; 3: 15972.
  • 7
    Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ III. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102: 125968.
  • 8
    Chiba N, Bernard L, O'Brien BJ, Goeree R, Hunt RH. A Canadian physician survey of dyspepsia management. Can J Gastroenterol 1998; 12: 8390.
  • 9
    Chiba N, Veldhuyzen van Zanten SJ, Sinclair P, Ferguson A, Escobedo S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment –Helicobacter pylori positive (CADET-Hp) randomized controlled trial. Br Med J 2002; 324: 10128.
  • 10
    Veldhuyzen van Zanten S, Chiba N, Armstrong D, et al. A double-blind randomised controlled trial comparing omeprazole (OME), ranitidine (RAN), cisapride (CIS), and placebo (PLA) in 512 Helicobacter pylori (Hp) negative primary care patients with uninvestigated dyspepsia (UD). The CADET-HN Study. Can J Gastroenterol 2002; 16(Suppl. A): A5(Abstract).
  • 11
    Armstrong D, Barkun AN, Chiba N, et al. ′Start high′– A better acid suppression strategy for heartburn-dominant uninvestigated dyspepsia (UD) in primary care practice (PCP) – The CADET-HR study. Gastroenterology 2002; 122(4): A472(Abstract).
  • 12
    Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of irritable bowel. Br Med J 1978; 2: 6534.
  • 13
    Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996; 111: 8592.
  • 14
    Armstrong D, Barkun AN, Grace EM, Schmuck ML, Shannon S. ‘Do you see what I see?’– Inter-observer agreement for upper GI endoscopy – (CADET-PE) (EGD) video clips in 30 endoscopists. Gastroenterology 2002; 122(4): A471(Abstract).
  • 15
    Talley N, Weaver AL, Tesmer DL, Zinsmeister AR. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology 1993; 105: 137886.
  • 16
    Talley NJ, Silverstein MD, Agreus L, Nyren O, Sonnenberg A, Holtman G. AGA technical review. evaluation of dyspepsia. Gastroenterology 1998; 114: 58295.
  • 17
    Statistics Canada website ( ).
  • 18
    Madsen LG, Bytzer P. The value of alarm features in identifying organic causes of dyspepsia. Can J Gastroenterol 2000; 14: 71620.
  • 19
    Moller Hansen J, Bytzer P, Schaffalitzky de Muckadell OB. Management of dyspeptic patients in primary care. Scand J Gastroenterol 1998; 33: 799805.
  • 20
    Lanssen AT, Pedersen FM, Bytzer P, Schaffalitzky de Muckadell OB. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomized trial. Lancet 2000; 356: 45560.
  • 21
    Stanghellini V, Anti M, Bianchi Porro G, et al. Risk indicators of organic disease in uninvestigated dyspepsia: a one-week survey in 246 Italian endoscopy units. Eur J Gastroenterol Hepatol 1999; 11: 112934.
  • 22
    Wallace MB, Durkalski VL, Palesch YY, et al. Age and alarm symptoms do not predict endoscopic findings among patients with dyspepsia: a multicentre database study. Gut 2001; 49: 2934.
  • 23
    Talley NJ, Colin-Jones D, Koch KJ, Koch M, Nyren O, Stanghellini V. Functional dyspepsia. a classification with guidelines for diagnosis and management. Gastroenterol Int 1994; 4: 14560.
  • 24
    Dent J, Jones R, Kahrilas P, Talley NJ. Management of gastro-oesophageal reflux disease in general practice. Br Med J 2001; 322: 3447.
  • 25
    Talley NJ, Axon A, Bytzer P, Holtman G, Lam SK, Van Zanten S. Management of uninvestigated and functional dyspepsia: a Working Party report for the World Congresses of Gastroenterology 1998. Aliment Pharmacol Ther 1999; 13: 113548.
  • 26
    Veldhuyzen van Zanten SJ, Pollack PT, Best LM, Bezanson GS, Marrie TJ. Increasing prevalence of Helicobacter pylori infection with age: continous risk of infection in adults rather than cohort effect. J Infect Dis 1994; 169: 4347.
  • 27
    Veldhuyzen van Zanten SJO, Sherman PM. Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview. Can Med Assoc J 1994; 150: 17785.
  • 28
    Kuipers EJ, Thijs JC, Festen HPM. The prevalence of Helicobacter pylori. In: Peptic Ulcer Disease. Aliment Pharmacol Ther 1995; 9(Suppl. 2): 5969.
  • 29
    Laine L. Review article. the effect of Helicobacter pylori infection on nonsteroidal anti-inflammatory drug-induced upper gastrointestinal tract injury. Aliment Pharmacol Ther 2002; 16(Suppl. 1): 349.
  • 30
    McColl KE, Murray LS, Gillen D, et al. Randomized trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H. pylori testing alone in the management of dyspepsia. Br Med J 2002; 324: 9991002.
  • 31
    Fallone CA, Barkun AN, Friedman G, et al. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol 2000; 95: 91420.
    Direct Link:
  • 32
    Warburton-Timms VJ, Charlett A, Valori RM, et al. The significance of cagA+Helicobacter pylori in reflux oesophagitis. Gut 2001; 49: 3416.
  • 33
    Chan FKL, Sung JJY, Chung SCS, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350: 9759.
  • 34
    Huang J-Q Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 1422.
  • 35
    Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 20338.
  • 36
    Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 96773.
  • 37
    Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Lancet 1998; 352: 101621.
  • 38
    Spechler SJ. Clinical practice. Barrett's esophagus. N Engl J Med 2002; 346: 83642.
  • 39
    Falk GW. Barrett's esophagus. Gastroenterology 2002; 122: 156991.